Xin Lang Cai Jing·2025-11-10 03:12Core Viewpoint - Bank of America Securities reports that BeiGene's Q3 product revenue reached $1.395 billion, a year-on-year increase of 40.4%, driven primarily by a 51% year-on-year growth in Brukinsa [1] Financial Performance - Total revenue for the quarter was $1.412 billion, reflecting a year-on-year growth of 41% [1] - Net profit for the period was $125 million, marking a turnaround from a loss to profitability [1] Guidance and Forecasts - Management has raised the full-year revenue guidance from $5 billion to $5.1-5.3 billion [1] - Based on the performance in the first three quarters, the firm has slightly adjusted its sales and other expense forecasts [1] - Earnings per share forecasts for 2025 to 2027 have been increased by 55.2%, 0.6%, and 0.4% respectively [1] Price Target and Rating - The target price for US shares has been raised from $389 to $402.2 [1] - The target price for H shares has been increased from HKD 234.9 to HKD 242.87 [1] - The "Buy" rating is reiterated based on strong global commercial performance and stable progress in the R&D pipeline [1]